{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-051210","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2024-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.082519+00:00","generated_at":"2026-06-01T05:15:45.959499+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Protara Therapeutics stockholders approve all five proposals at 2024 Annual Meeting","bullets":["Class I directors elected: Jane Huang (9.66M for), Richard Levy (9.64M for), Michael Solomon (9.56M for); broker non-votes 3.81M.","Ratification of Ernst & Young as auditor: 13.40M for, 189,574 against, 1,424 abstentions.","Advisory vote on exec compensation approved: 7.00M for, 196,457 against, 2.59M abstentions plus broker non-votes.","2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan both approved: 9.60M and 9.65M for, respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-051210","json":"https://secwatch.observer/filing/0001213900-24-051210.json","markdown":"https://secwatch.observer/filing/0001213900-24-051210.md","text":"https://secwatch.observer/filing/0001213900-24-051210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024051210/0001213900-24-051210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390024051210/ea0207579-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:15:45.959499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}